首页> 外文期刊>BMC Cancer >Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer
【24h】

Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer

机译:血清蛋白酶作为生物标志物,用于预测放疗和无小细胞肺癌放射治疗和无线电化疗中的存活率,招诊断和远处转移率

获取原文
           

摘要

Several studies have documented that blood biomarkers can improve basic prognostic models in radiotherapy and radio-chemotherapy for non-small cell lung cancer. The current study evaluated the prognostic impact of six markers focusing on their utility in homogenous subsets, compared to the significance in a large heterogeneous group. Blood samples of 337 patients who were referred for curative or palliative external beam thoracic radiotherapy for non-small cell lung cancer were collected. The concentration of osteopontin (OPN), vascular endothelial growth factor (VEGF), erythropoetin (EPO), high mobility group box?1 protein (HMGB1), insulin-like growth factor 1 (IGF-1) and platelet-derived growth factor (PDGF) in serum were measured by ELISA assay and the prognostic potential was assessed using univariable and multivariable survival models. Multivariable analysis revealed that out of several variables studied six dichotomized features: namely: cigarette smoking, lack of chemotherapy, palliative doses of radiotherapy, high OPN concentration, advanced T stage and high VEGF concentration had a highly significant (p??0.005) and independent influence on overall survival in the group of 337 patients. In a subset of patients treated with curative radio-chemotherapy or radiotherapy (N?=?148) tumor pathology, EPO concentration and VEGF concentration, significantly and independently influenced overall survival. In a subset of patients with squamous cell cancer (N?=?206) OPN had a highly significant impact on overall survival. In contrast, in a subset of patients with nonsquamous histology (N?=?131) only VEGF had a significant influence on survival. Blood serum proteins appear to be clinically useful prognosticators of overall survival in radio-chemotherapy and radiotherapy for non-small cell lung cancer. In unselected heterogeneous groups, dichotomized concentrations of OPN and VEGF emerged among the strongest independent prognosticators of overall survival. VEGF and EPO concentration (dichotomized) were found to be independent prognostic factors among the patients treated with curative doses of radiotherapy. The utility of OPN as a prognostic marker appeared restricted to the patients with squamous histology.
机译:几项研究记录了血液生物标志物可以改善非小细胞肺癌放射治疗和无线电化疗中的基本预后模型。目前的研究评估了六种标记对其在均匀子集中效用的预后影响,而与大型异质组中的意义相比。收集了337名患者的血液样本,用于针对非小细胞肺癌的疗效或姑息的外束胸部放射治疗。骨桥蛋白(OPN),血管内皮生长因子(VEGF),促红细胞素(EPO),高迁移率组箱的浓度,高迁移率组箱α1蛋白(HMGB1),胰岛素样生长因子1(IGF-1)和血小板衍生的生长因子(通过ELISA测定法测量血清中的PDGF,使用单变量和多变量的存活模型评估预后潜力。多变量的分析显示,除了几种分数的变量中,六分类特征:即:香烟吸烟,缺乏化疗,姑息剂量的放疗,高opn浓度,高级T阶段和高VEGF浓度具有极大的显着(p?<0.005)和对337例患者组总生存的独立影响。在患有治疗无线电化疗或放射治疗的患者的子集中(n?= 148)肿瘤病理,EPO浓度和VEGF浓度,显着且独立地影响了整体存活。在鳞状细胞癌的患者的子集中(n?= 206)OPN对整体生存产生了非常重大的影响。相比之下,在非问题组织学患者的患者中(n?= 131)只有VEGF对存活产生重大影响。血清血清蛋白似乎是无线电化疗的整体存活的临床有用的预测因子,以及非小细胞肺癌的放射疗法。在未选择的异构组中,在整体存活的最强大的独立预后,OPN和VEGF的二分浓度浓度。发现VEGF和EPO浓度(二分法)被发现是用疗效放射治疗的患者的独立预后因素。作为预后标志物的opn的效用似乎仅限于鳞状组织学的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号